These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 32761467

  • 1. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
    Taguchi S, Ohtake T, Mochida Y, Ishioka K, Moriya H, Hidaka S, Kobayashi S.
    Clin Exp Nephrol; 2020 Dec; 24(12):1132-1139. PubMed ID: 32761467
    [Abstract] [Full Text] [Related]

  • 2. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
    Papakrivopoulou E, Shendi AM, Salama AD, Khosravi M, Connolly JO, Trompeter R.
    Nephrology (Carlton); 2016 Oct; 21(10):893-900. PubMed ID: 26860320
    [Abstract] [Full Text] [Related]

  • 3. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
    Fujimoto K, Kagaya Y, Kumano S, Fujii A, Tsuruyama Y, Matsuura T, Yamazaki K, Nomura K, Okada K, Okino K, Adachi H, Furuichi K, Yokoyama H.
    Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
    Zhang J, Zhao H, Li X, Qian R, Gao P, Lu S, Ma Z.
    BMC Nephrol; 2023 Apr 26; 24(1):112. PubMed ID: 37101300
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
    Katsuno T, Masuda T, Saito S, Kato N, Ishimoto T, Kato S, Kosugi T, Tsuboi N, Kitamura H, Tsuzuki T, Ito Y, Maruyama S.
    Clin Exp Nephrol; 2019 Feb 26; 23(2):207-214. PubMed ID: 30121802
    [Abstract] [Full Text] [Related]

  • 6. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
    Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, Guigonis V, Ducret F, Presne C, Pirson Y, Hourmant M, Glachant JC, Vendrely B, Moranne O, Faguer S, Chauveau D.
    Nephrol Dial Transplant; 2014 Nov 26; 29(11):2084-91. PubMed ID: 24920841
    [Abstract] [Full Text] [Related]

  • 7. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T.
    Clin Exp Nephrol; 2017 Aug 26; 21(4):671-676. PubMed ID: 27558467
    [Abstract] [Full Text] [Related]

  • 8. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.
    Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K.
    Pediatr Nephrol; 2010 Mar 26; 25(3):539-44. PubMed ID: 20049616
    [Abstract] [Full Text] [Related]

  • 9. Rituximab in Steroid-Dependent Podocytopathies.
    Costa C, Antunes A, Oliveira J, Pereira M, Godinho I, Fernandes P, Jorge S, Lopes JA, Gameiro J.
    Glomerular Dis; 2024 Mar 26; 4(1):129-136. PubMed ID: 39144474
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, Smith KG, Jayne DR.
    Rheumatology (Oxford); 2015 Jul 26; 54(7):1153-60. PubMed ID: 25477054
    [Abstract] [Full Text] [Related]

  • 11. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N.
    BMC Nephrol; 2020 Apr 15; 21(1):134. PubMed ID: 32293308
    [Abstract] [Full Text] [Related]

  • 12. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
    Hoxha E, Stahl RA, Harendza S.
    Clin Nephrol; 2011 Aug 15; 76(2):151-8. PubMed ID: 21762648
    [Abstract] [Full Text] [Related]

  • 13. Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease.
    Liu D, Zhou Z, Wang M, Nie S, Li J, Hu B, He W, Wang G, Ai J.
    BMC Nephrol; 2021 Jul 01; 22(1):242. PubMed ID: 34210283
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L, Lin Y, Yu B, Wang Y, Pan H, Wang H, Lou X, Lang X, Zhang Q, Jin L, Yang Y, Xiao L, Chen J, Han F.
    Am J Nephrol; 2024 Jul 01; 55(1):25-36. PubMed ID: 37963441
    [Abstract] [Full Text] [Related]

  • 15. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
    Ohyama R, Fujinaga S, Sakuraya K, Hirano D, Ito S.
    Clin Exp Nephrol; 2023 Oct 01; 27(10):865-872. PubMed ID: 37477752
    [Abstract] [Full Text] [Related]

  • 16. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
    Hogan J, Dossier C, Kwon T, Macher MA, Maisin A, Couderc A, Niel O, Baudouin V, Deschênes G.
    Pediatr Nephrol; 2019 Feb 01; 34(2):253-259. PubMed ID: 30109447
    [Abstract] [Full Text] [Related]

  • 17. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
    Ma X, Fang L, Sheng L, Zhou X, Bai S, Zang X, Wang Y, Li M, Lv Z, Zhong Q, Yang X, Wang Y, Hu Y, Yan D, Shi Y, Chen H, Li J, Tao M, Zhuang S, Wang Y, Liu N.
    Ren Fail; 2023 Dec 01; 45(1):2237124. PubMed ID: 37482915
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J, Du J, Wang S, Xiao L, Zhao X.
    Zhonghua Er Ke Za Zhi; 2014 Jul 01; 52(7):521-4. PubMed ID: 25224058
    [Abstract] [Full Text] [Related]

  • 19. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
    Lin L, Wang W, Wu Y, Xie J, Li X, Pan X, Zhang W, Xu J, Cai Y, Ren H, Chen N.
    Drug Des Devel Ther; 2021 Jul 01; 15():1945-1953. PubMed ID: 34007154
    [Abstract] [Full Text] [Related]

  • 20. Short-Term Steroid Regimen for Adult Steroid-Sensitive Minimal Change Disease.
    Ozeki T, Katsuno T, Hayashi H, Kato S, Yasuda Y, Ando M, Tsuboi N, Hagiwara D, Arima H, Maruyama S.
    Am J Nephrol; 2019 Jul 01; 49(1):54-63. PubMed ID: 30557879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.